November 26, 2015
NICE recommends drugs to treat 4 different medical conditions
The National Institute for Health and Care Excellence (NICE) has published its final recommendations on whether six different drug treatments…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
November 26, 2015
LEO Pharma appoints Svend Andersen EVP head of Europe+
LEO Pharma has named Svend Andersen as incoming EVP, Head of Region EUROPE+, who will assume the position of Executive Vice President, Head of Region EUROPE+, on January 1, 2016. He will join LEO Pharma’s Executive Leadership Team and report directly to the CEO.
November 26, 2015
Teva to receive global development and commercial rights to Hemtares’ novel CGRP antagonists
Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Sosei Group’s subsidiary Heptares, for the treatment of migraine.
November 26, 2015
Amgen’s first Humira biosimilar application for ABP 501 to the FDA
Amgen has filed a Biologics License Application (BLA) with the United States (U.S.) Food and Drug Administration (FDA) for ABP 501,…
November 25, 2015
Glades Drugs recalls its Vitamin D3 capsules
Glades Drugs has voluntarily recalled its Vitamin D3 capsules
November 25, 2015
Allergan settles with New York over Memantine. Agrees to pay $170K for state’s litigation expenses
Allergan has agreed with the New York State Attorney General’s Office to end the litigation under Section 2 of the Sherman Act, and other statutes with the Attorney General over the decision of Forest Laboratories
November 25, 2015
U.S. politicians slam tax-avoiding Pfizer-Allergan deal
U.S. politicians condemned Pfizer Inc’s deal with Allergan Plc as a tax dodge on Monday, bringing another round of hand-wringing in Washington over the corporate tax code, though legislative action before 2017 is unlikely.
November 25, 2015
Allergan and Rugen Therapeutics to jointly support novel therapies Autism Spectrum Disorders
Allergan plc, a company recently bought by Pfizer, and Rugen Therapeutics will jointly support the discovery and development of novel therapies for Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD).
November 25, 2015
Hikma sells ex-Ben Venue factory in Bedford to Xellia
Hikma Pharmaceuticals will sell its manufacturing facilities previously owned by Ben Venue Laboratories based in Bedford, Ohio, to Xellia Pharmaceuticals. In 2014,…
November 25, 2015
Anavex promotes a vice president regulatory affairs
Kristina M. Capiak, CCRP has been promoted the Anavex Life Sciences Corp’s Vice President of Regulatory Affairs. She is overseeing U.S. and international regulatory matters for Anavex, including filings and interactions with the FDA and other regulatory authorities.
You must be logged in to post a comment.